Biogen reprioritizes Alzheimer’s disease resources, discontinues ADUHELM development
Biogen Inc. (Nasdaq: BIIB), a leading pharmaceutical company, today announced a strategic reprioritization of its resources in Alzheimer’s disease (AD), a key therapeutic area expected ... Read More
Arkuda Therapeutics gets $64m booster to advance neurodegenerative treatment
Arkuda Therapeutics, a US-based biotechnology company, has raised $64 million in Series B financing. The new funding will help Arkuda Therapeutics boost the production of ... Read More
BrainStorm Cell Therapeutics doses patients in NurOwn phase 3 trial in ALS
NurOwn phase 3 trial : BrainStorm Cell Therapeutics, a US biotech company engaged in developing adult stem cell therapies for neurodegenerative diseases, has completed the ... Read More
CMD enrolls first patient in placebo-controlled ALS trial of CuATSM
Collaborative Medicinal Development (CMD) has enrolled the first patient in a placebo-controlled clinical trial to evaluate the safety and efficacy of CuATSM in patients with ... Read More
Multiple Sclerosis symptoms may worsen with consumption of Soda, Sugar sweetened beverages
If people with multiple sclerosis consume 290 calories of soda or sugar sweetened beverages a day, their symptoms may worsen as warned by the researchers. ... Read More